Assenagon Asset Management S.A. increased its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,476 shares of the company’s stock after acquiring an additional 6,642 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Johnson & Johnson were worth $14,176,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of JNJ. Innealta Capital LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $27,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the last quarter. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth about $43,000. Fairfield Financial Advisors LTD bought a new position in Johnson & Johnson in the 2nd quarter valued at about $46,000. Finally, Fairway Wealth LLC boosted its stake in Johnson & Johnson by 217.1% during the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after purchasing an additional 228 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Buying and Selling
In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $160.88 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a fifty day simple moving average of $163.41 and a two-hundred day simple moving average of $155.07. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $387.28 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the company earned $2.66 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is currently 71.78%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.